MX2020007941A - Metodo para prevenir o tratar enfermedad de alzheimer. - Google Patents

Metodo para prevenir o tratar enfermedad de alzheimer.

Info

Publication number
MX2020007941A
MX2020007941A MX2020007941A MX2020007941A MX2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A
Authority
MX
Mexico
Prior art keywords
disease
preventing
treating alzheimer
subject
dapansutrile
Prior art date
Application number
MX2020007941A
Other languages
English (en)
Spanish (es)
Inventor
Charles A Dinarello
Original Assignee
Olatec Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Llc filed Critical Olatec Therapeutics Llc
Publication of MX2020007941A publication Critical patent/MX2020007941A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020007941A 2018-01-31 2019-01-31 Metodo para prevenir o tratar enfermedad de alzheimer. MX2020007941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862624637P 2018-01-31 2018-01-31
PCT/US2019/016012 WO2019152627A1 (en) 2018-01-31 2019-01-31 Method for preventing or treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2020007941A true MX2020007941A (es) 2020-09-03

Family

ID=67478566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007941A MX2020007941A (es) 2018-01-31 2019-01-31 Metodo para prevenir o tratar enfermedad de alzheimer.

Country Status (7)

Country Link
US (1) US11517554B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746057B1 (cg-RX-API-DMAC7.html)
JP (1) JP7290872B2 (cg-RX-API-DMAC7.html)
CN (1) CN111670032A (cg-RX-API-DMAC7.html)
CA (1) CA3087865A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020007941A (cg-RX-API-DMAC7.html)
WO (1) WO2019152627A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7229565B2 (ja) * 2018-03-21 2023-02-28 オラテック セラピューティクス リミティド ライアビリティ カンパニー メラノーマを治療するための方法
EP4045009A4 (en) 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER
EP4387729A4 (en) * 2021-08-19 2025-07-09 Olatec Therapeutics Inc METHODS OF TREATMENT OF PARKINSON'S DISEASE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006708A (es) 2010-12-15 2013-09-13 Olatec Ind Llc Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor.
CN104869993B (zh) * 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
CA2911547A1 (en) * 2013-05-31 2014-12-04 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat alzheimer's disease
WO2015165961A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ES2879678T3 (es) * 2015-02-26 2021-11-22 Univ Kentucky Res Found Composiciones y procedimientos para el tratamiento de la degradación retiniana

Also Published As

Publication number Publication date
JP7290872B2 (ja) 2023-06-14
US20200352897A1 (en) 2020-11-12
EP3746057B1 (en) 2024-03-20
US11517554B2 (en) 2022-12-06
CN111670032A (zh) 2020-09-15
CA3087865A1 (en) 2019-08-08
WO2019152627A1 (en) 2019-08-08
JP2021512086A (ja) 2021-05-13
EP3746057A1 (en) 2020-12-09
EP3746057A4 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
AU2017291414B2 (en) Anti-N3pGLu amyloid beta peptide antibodies and uses thereof
MX2021010696A (es) Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.
PH12021500006A1 (en) Methods of treatment and prevention of alzheimer's disease
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MX2023007998A (es) Regimenes de tratamiento con dexmedetomidina.
MX2022010748A (es) Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
FI3445351T3 (fi) Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2024000701A (es) Metodos de tratamiento de la enfermedad de alzheimer.
BR112023017999A2 (pt) Obicetrapibe para tratamento de demências
EA202192928A1 (ru) Терапевтическое лекарственное средство для лечения дискинезии
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
FR3079141B1 (fr) Utilisations de derives de curcumine
MY193963A (en) Composition for treating joint diseases and kit containing same
EA202190406A1 (ru) Способы лечения нейродегенеративных расстройств
JP2021512086A5 (cg-RX-API-DMAC7.html)
MX2024007043A (es) Purinas y métodos de uso.
MX2024005084A (es) Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada.
MX2019003720A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.